The Nature and Influence of Pharmaceutical Industry Involvement in Asthma Trials
BACKGROUND: Pharmaceutical industry-sponsored research has been shown to be biased toward reporting positive results. Frequent industry participation in trials assessing the efficacy of inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination treatment makes assessing industry i...
Saved in:
| Main Authors: | Kenneth Bond, Carol Spooner, Lisa Tjosvold, Catherine Lemière, Brian H Rowe |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Canadian Respiratory Journal |
| Online Access: | http://dx.doi.org/10.1155/2012/890457 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Increasing the Use of Anti-Inflammatory Agents for Acute Asthma in the Emergency Department: Experience with an Asthma Care Map
by: Brian H Rowe, et al.
Published: (2008-01-01) -
Applying the risk of bias tool in a systematic review of combination long-acting beta-agonists and inhaled corticosteroids for persistent asthma.
by: Lisa Hartling, et al.
Published: (2011-02-01) -
Barriers to the Recognition and Reporting of Occupational Asthma by Canadian Pulmonologists
by: Anu Parhar, et al.
Published: (2011-01-01) -
Canadian Thoracic Society Asthma Committee Commentary on Long-Acting Beta-2 Agonist Use for Asthma in Canada
by: M Diane Lougheed, et al.
Published: (2010-01-01) -
Work-Related Asthma: A Case-Based Guide
by: Susan M Tarlo, et al.
Published: (2009-01-01)